Celldex Therapeutics (CLDX) Posts Narrower than Expected Q4 Loss

Celldex Therapeutics (NASDAQ: CLDX) reported Q4 EPS of ($0.24), $0.04 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $2.26 million.

For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Anthropic delays planned IPO from October to November - WSJ
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2